Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Clinical outcomes and total IgE changes with omalizumab and dupilumab in moderate-to-severe asthma: a retrospective real-world cohort study.

Created on 04 Nov 2026

Authors

Yan Chen, Boyun Yang, Wo Yao, Ran Diao, Yongfang Wang, Bohui Li, Ting Li, Liuya Ge, Yingying Hu, Huiying Wang

Published in

Frontiers in medicine. Volume 13. Pages 1964856. Epub Oct 20, 2026.

Abstract

Direct real-world comparisons of omalizumab (OMA) and dupilumab (DUP) for moderate-to-severe asthma remain limited. We compared clinical and biomarker changes during treatment with these biologics.
This retrospective, single-center, real-world cohort included 72 adults who initiated OMA (n = 48) or DUP (n = 24) between January 2024 and December 2025 and continued treatment through approximately 4 months. Outcomes were assessed at baseline and approximately 4 and 12 months. Exploratory analyses compared four-month changes between groups, and available repeated measurements were evaluated using adjusted linear mixed-effects models.
Both OMA and DUP treatments were associated with improved asthma control and pulmonary function at 4 months, with no clear between-group differences in changes in Asthma Control Test (ACT) score, blood eosinophil count, fractional exhaled nitric oxide, or pulmonary function parameters. Adjusted models showed improvements over time in ACT score (P < 0.001) and percent-predicted forced expiratory volume in one second (P = 0.002), without significant treatment-group effects or treatment-by-time interactions. Serum total immunoglobulin E (IgE) increased with OMA and decreased with DUP at 4 months, with a significant four-month treatment-by-time interaction (P < 0.001) in the longitudinal model.
In this cohort, OMA and DUP were each associated with improvements in asthma control and pulmonary function, with no clear between-group differences detected. Their differing 4-month changes in serum total IgE were consistent with differences in their pharmacodynamic effects.

PMID:
42978889
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 73
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement